Skip to main content
BUKWANG PHARMACEUTICAL IND CO.,LTD logo

BUKWANG PHARMACEUTICAL IND CO.,LTD — Investor Relations & Filings

Ticker · 003000 ISIN · KR7003000007 KO Manufacturing
Open in API
Filings indexed 327 across all filing types
Latest filing 2026-06-02 Regulatory Filings
Country KR South Korea
Listing KO 003000

About BUKWANG PHARMACEUTICAL IND CO.,LTD

https://www.bukwang.co.kr/en/

Bukwang Pharmaceutical is a research and development-focused company that develops, produces, and sells a range of pharmaceutical and oral hygienic products. The company emphasizes an open innovation strategy, leveraging joint ventures, research collaborations, and strategic investments to build a robust drug pipeline. Its key development areas include treatments for central nervous system disorders like schizophrenia, bipolar depression, and dyskinesia in Parkinson's disease. The pipeline also features oncology candidates, such as a treatment for metastatic prostate cancer. Bukwang Pharmaceutical manufactures various dosage forms, including oral solids and injections, alongside over-the-counter medications.

Recent filings

Filing Released Lang Actions
투자판단관련주요경영사항 ((라투다정의 추가 적응증 3상 임상시험계획(IND) 승인)
Regulatory Filings Classification · 85% confidence The document is a Korean ‘투자판단 관련 주요경영사항’ disclosure (from KRX/DART), detailing the IND approval for a Phase 3 clinical trial. It is not a financial report, earnings release, management change, or similar category, but rather a general regulatory announcement of a material business event. Therefore it falls under the fallback “Regulatory Filings (RNS).”
2026-06-02 Korean
기업지배구조보고서공시
Governance Information Classification · 95% confidence The document is titled “기업지배구조 보고서” (Corporate Governance Report) and contains detailed descriptions of the company’s governance policies, board and committee structures, shareholder meeting procedures, key governance indicators, and compliance with Korean corporate governance guidelines. It is not a financial statement (10-K/IR), a proxy or voting result notice (DVA), nor an AGM presentation or call transcript, but rather a governance practice disclosure. This clearly aligns with the Governance Information category (CGR).
2026-06-01 Korean
대규모기업집단현황공시[연1회공시및1/4분기용(개별회사)]
Regulatory Filings Classification · 92% confidence The document is a detailed statutory disclosure of corporate group status, affiliate information, and intercompany transactions under Korean regulations (Fair Trade Act), not an annual or interim financial report, earnings release, or any other specified report type. It is a compliance/regulatory filing rather than a presentation or actual financial statements for reporting purposes. Thus, it falls into the generic regulatory announcements category (RNS).
2026-05-29 Korean
분기보고서 (2026.03)
Interim / Quarterly Report Classification · 98% confidence The document is titled ‘분기보고서 (제 67기 1분기)’ covering the period 2026.01.01–2026.03.31 and contains full financial statements, notes, business descriptions, management analysis, and auditor’s opinion. It is a comprehensive quarterly filing rather than an announcement of a report. This matches the definition of an Interim/Quarterly Report (Code: IR). Q1 2026
2026-05-14 Korean
[기재정정]타법인주식및출자증권취득결정
M&A Activity Classification · 85% confidence The document is a public disclosure of a board resolution and corrective notice regarding the company's decision to acquire shares and equity securities of another corporation (한국유니온제약). It provides detailed information on the number of shares, acquisition amount, ownership percentages, and anticipated acquisition date. This constitutes an announcement of an acquisition/takeover transaction, fitting the M&A Activity category rather than a routine financial report or regulatory filing. Therefore, it should be classified under M&A Activity (TAR).
2026-05-13 Korean
타법인주식및출자증권취득결정
M&A Activity Classification · 92% confidence The document is a regulatory disclosure detailing a board resolution to acquire 60,000,000 shares (74.97%) of another company via third-party allotment, including acquisition price, purpose, method, timeline, and financial summaries of the target. This constitutes an M&A/takeover announcement rather than an earnings release or financing update. Therefore it fits the M&A Activity category (TAR).
2026-04-27 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.